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Abstract
Phase I testing of investigational drugs relies on healthy volunteers as research participants. Many 
U.S. healthy volunteers enroll repeatedly in clinical trials for the financial compensation. Serial 
participants are incentivized to ignore restrictions on their participation, and no centralized clinical 
trial registry prevents dual enrollment. Little is currently known about how healthy volunteers 
participate in studies over time, hampering the development of policies to protect this group. We 
detail a methodology developed as part of a longitudinal study to track in real-time healthy 
volunteers’ Phase I participation. Illustrating these data through three case studies, we document 
how healthy volunteers use strategies, such as qualifying for studies at more than one clinic and 
traveling significant distances, to maximize their participation. Our findings suggest that “clinical 
trial diaries” can generate critical information about serial research participation and point to 
ethical issues unique to healthy volunteers’ involvement in Phase I clinical trials.
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Phase I testing of new pharmaceuticals relies primarily on healthy volunteers as research 
participants. These clinical trials are designed to assess the safety of investigational drugs 
and help to establish doses for later-phase, efficacy trials. In the U.S. context, most of these 
clinical trials are conducted at dedicated in-patient clinics owned and operated by contract 
research organizations, independent research companies, or pharmaceutical companies 
(Fisher, 2009). Healthy volunteers are recruited through advertising and word-of-mouth, 
with the promise of stipends in exchange for their participation (Almeida, Azevedo, Nunes, 
Vaz-da-Silva, & Soares-da-Silva, 2007). Payments range considerably based on the length 
of the study, but clinics typically compensate volunteers at the rate of US$100 to US$300 
per day (Camporesi & McNamee, 2014). For studies that require a 30-day stay in the clinic, 
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participants can earn nearly US$10,000. Healthy volunteers can also receive nominal 
payments for screening visits (e.g., US$25) or for being an “alternate” (e.g., US$100), which 
is a term used to describe someone who checks into a clinic for a study in case any of the 
confirmed participants cannot be enrolled and need to be replaced on the day of dosing 
(Abadie, 2010).
Motivated by these financial incentives, most healthy volunteers in Phase I clinical trials are 
serial participants who enroll repeatedly in studies (Fisher, 2014, 2015; Tishler & 
Bartholomae, 2003). Some healthy volunteers become “professional” research participants, 
treating Phase I trials as full-time work and travel around the United States to maximize the 
income they earn (Abadie, 2010). Others are regular participants who use stipends to 
supplement their household income, some of which is frequently used to purchase expensive 
consumer goods (Tolich, 2010). Although healthy volunteers are often assumed to be young, 
White university students, U.S. Phase I trials enroll diverse participants, including what 
might be considered an overrepresentation of racial and ethnic minorities (Fisher & 
Kalbaugh, 2011). Men, nonetheless, predominate as healthy volunteers, either because of 
self-selection or inclusion–exclusion criteria that restrict the types of studies in which 
women of childbearing potential can enroll (Corrigan, 2002; Fisher & Ronald, 2010; Wood, 
2009; Yang et al., 2009).
Typically, Phase I trials require a 30-day washout period before participants can enroll in a 
new study. There is, however, no single central registry of trial participants, so healthy 
volunteers can generally avoid restrictions on how often they enroll in studies by 
participating in multiple clinics (Resnik & Koski, 2011). Although Phase I investigators 
estimate the rate of serious adverse events to occur in fewer than 1% of healthy volunteers 
(Hedgecoe, 2014; Kumagai et al., 2006; Sibille, Donazzolo, Lecoz, & Krupka, 2006), dual 
enrollment in clinical trials can increase participants’ risk of harm as well as raise validity 
concerns (Kupetsky-Rincon & Kraft, 2012). There are no published data on the extent of 
dual enrollment in Phase I trials, but 10% of participants in one empirical study admitted to 
enrolling simultaneously in more than one study (Kass, Myers, Fuchs, Carson, & Flexner, 
2007).
The evidence base for why healthy people enroll in Phase I trials is solid, but virtually 
nothing is known about healthy volunteers’ serial participation in medical research over 
time. Even if healthy volunteers are financially motivated to enroll in clinical trials, this does 
not explain how they make decisions about participating in certain studies or specific clinics 
and over what timeframes. Although some scholars voice concern about healthy volunteers’ 
subversive behaviors (Abadie, 2010; Dickert, 2013; Dresser, 2013), there is little evidence 
of the prevalence of rule breaking in Phase I trials (Devine et al., 2013). Similarly, little is 
known about how various aspects of participation in Phase I studies such as experiencing 
adverse effects may influence subsequent behaviors related to study participation. Because 
of a dearth of available data to help policymakers create appropriate policies for the 
protection of Phase I participants, this group is uniquely vulnerable in clinical research. This 
article reports on a research tool we developed as part of a larger study to collect such data 
by tracking in real-time healthy volunteers’ participation in Phase I trials, and it illustrates 
the kinds of data this tool can provide.
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We developed a web-based “clinical trial diary” (CTD) to capture information on every 
Phase I clinical trial for which healthy volunteers screen while enrolled in the 
HealthyVOICES Project (N = 180). This longitudinal, mixed-methods study is designed to 
measure the relationship over time between healthy volunteers’ perceptions of the risks and 
benefits of Phase I participation and their decision making and behaviors surrounding 
enrollment in specific clinical trials. The study was designed with two arms—“full 
participation” and control—to which all participants were randomized after enrollment. The 
full-participation arm includes completion of CTDs and participation in five semi-structured 
interviews (at enrollment, at 6 months, 1 year, 2 years, and 3 years) over 3 years. The 
control arm includes two semi-structured interviews only (at enrollment and 3 years). The 
purpose of the control group is to evaluate whether the CTDs and additional interviews have 
an unintended interventional effect on volunteers over the course of the study. Participants 
in our study were assigned to groups based on their level of experience in clinical studies 
using a randomization module developed in REDCap (Harris et al., 2009) that allocated 20% 
of the participants to the control group. Participants receive compensation for participation 
in interviews at scheduled time points; however, they are not compensated for completing 
CTDs so as not to encourage enrollment in Phase I trials.
All participants in our study were recruited while enrolled in clinical trials at seven Phase I 
clinics across the United States. The clinics were selected to represent a sample of for-profit 
and academic clinics of various sizes, study volumes, and geographic locations, each with a 
clinical research portfolio dedicated to early-phase pharmaceutical research. We recruited 
our sample from May to December 2013 in roughly equal portions from the East, Midwest, 
and West. Although our recruitment strategy was limited to seven clinics, our participant 
population circulates among a larger number of clinics, enabling us to capture information 
on nearly all Phase I facilities in the United States and expanding the representativeness of 
our sample as well as the generalizability of our findings (see case studies below for extent 
of participant travel to various U.S. clinics).
Participants were enrolled in eight cohorts during 2- to 5-day recruitment visits to each 
clinic (with a return visit to one clinic), enabling us to stagger data collection into discrete 
time points for each cohort. In total, we enrolled 180 participants in our study. Table 1 
shows the characteristics of our sample, which is representative of U.S. Phase I healthy 
volunteers more broadly (Fisher & Kalbaugh, 2011). Our sample is predominantly male 
with more than 60% of participants between the ages of 30 and 49. Few participants (n = 6) 
are aged between 18 and 21 years, indicating that Phase I healthy volunteers are not 
predominantly college students (in spite of the fact that six of our seven recruitment clinics 
were located in cities with one or more large universities). Forty percent of participants are 
Black, whereas roughly 30% are non-Hispanic Whites and 20% are Hispanic. The level of 
experience in clinical studies varied across our sample. Roughly 20% were participating in 
their first clinical trial during enrollment in our study, and almost 30% had participated in 2 
to 4 studies, whereas approximately 25% had participated in 5 to 10 studies and another 
25% had participated in 11 to 200 studies. At the time of this writing, 14 participants (7.8%) 
had voluntarily withdrawn, been removed from the study, or lost to follow-up.1
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Design of CTD System
The HealthyVOICES Project is ongoing, but here we focus on the completed design and 
implementation of the CTD system and report preliminary data from three participants’ 
CTDs. The CTD is a secure, web-based data collection tool, where participants in the full-
participation arm of our study enter information about clinical studies in which they have 
screened during the 3 years they are participating in our study. The CTD was developed to 
provide detailed information about the clinical trials they are screening for and participating 
in. Participants can access the CTD system on a smart phone or computer by logging into a 
password-protected online “CTD portal” using their email address and birthdate and can 
create new CTDs whenever they have a new study to report. The CTD itself is a three-part 
survey designed to mirror participants’ stage in the study participation process: (a) 
screening, (b) qualifying, and (c) participating (Figure 1). Part 1 collects information from 
the participants’ screening visit for a new clinical trial. In addition to collecting data about 
the clinical trials themselves, participants report how they found out about the clinical trial, 
their motivations to participate, and their perceptions of the likelihood of them participating 
in the study. Part 2 collects information about whether the participant qualified for the study. 
This part uses branching logic. If the participants did not qualify, they are asked the reason. 
If participants qualified, they are asked if they intend to participate in the study. If they do 
not intend to participate, they are asked why they have declined participation. The CTD is 
concluded at this stage for participants who did not qualify or decided not to participate in 
the study at hand. For those participants who report that they qualified and intend to 
participate, they fill out Part 3 of the CTD. This part allows them to report their experiences 
in the study in terms of adverse effects and interactions with research staff and other 
participants, as well as how willing they would be to participate in a similar clinical trial in 
the future.
The CTD system is designed to automate receipt of Parts 2 and 3 based on information 
healthy volunteers report in Part 1 and relies on a timeline typical to Phase I clinics. 
Specifically, if at the end of Part 1, participants respond that they do not yet know whether 
they qualify, the survey generates an email with a 3-day delay. When participants receive 
the email, they can click on hyperlinks that will let them start Part 2 if they know whether 
they have qualified for the study or will trigger a second email to be delivered 1 day later. If 
participants report in Part 2 that they intend to participate in the study, an email requesting 
them to complete Part 3 is sent to them 2 days after their last study visit using dates they 
provided for the clinical trial and the reported study duration. We also included questions 
1Of the 180 healthy volunteers enrolled, 14 are no longer participating in the broader study. One of these participants had been 
randomized to the control group, and the other 13 were randomized to the full-participation group. We removed 2 participants from 
the study when we discovered that they were actually only one person who had enrolled twice, using an alias and different 
demographic information the second time. We made the decision to exclude all of her data (which included only two baseline 
interviews and demographics), when we discovered her dual enrollment. Three additional participants exercised their right to 
withdraw from the study after being contacted to remind them to complete their clinical trial diaries (CTDs). The additional 9 
participants have been lost to follow-up. Four out of 9 completed at least one CTD before we lost contact with them. Efforts to reach 
these participants were stopped after no contact had been made for more than 6 months, and the participants had not only missed their 
second semi-structured interview at the 6-month mark but also the third round of interviewing at the 1-year mark due to begin. The 
demographics of these participants mirrored those of the entire sample, which means that the distribution of participants by sex and 
race/ethnicity for the study remains the same without these 14 participants.
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that will allow participants to complete all three parts of the CTD if they initiate it after the 
clinical trial is already completed.
CTD Data Quality and Compliance
Although self-reported data are imperfect, the CTD has a number of mechanisms to ensure 
that the information captures a full spectrum of outcomes in Phase I trial participation. For 
example, there are several questions that ask the respondent to confirm that data they entered 
in previous sections of a CTD are accurate (see online appendix, available at 
jre.sagepub.com/supplemental). In addition, in Part 3 of the CTD, respondents are asked to 
confirm that the study they participated in began on the start date they noted in Part 1. If the 
start date changed, branching logic allows an updated start date to be given. As Phase I 
clinics often invite more people to participate than dictated by the protocol to ensure full 
enrollment in studies, qualifying and being selected for a study do not guarantee 
participation. For example, “alternates” typically check into the clinic for Phase I trials, but 
they are only used if other participants do not or cannot proceed with the study. To allow for 
this contingency, Part 3 begins with a question about whether the healthy volunteer 
participated as planned and completed the study. If they did not complete participation, they 
are asked for the reason, including the option to report that they were an “alternate” for the 
study and were not selected to participate. As the CTD system is designed to ascertain 
various pathways of participation that are sensitive to the dynamics of Phase I studies, CTD 
data can provide an accurate picture of behaviors related to study enrollment. Study 
participants are also encouraged to use clinical trial informed consent documents when 
completing their CTDs to provide more accurate and complete information about those 
studies. Scheduled interviews at specified time points in our 3-year study provide another 
opportunity to verify the accuracy of CTD data.
As part of compliance efforts, project staff follow up with participants via email and phone 
to ensure that completion of CTDs matches the actual screening and enrollment behaviors of 
participants in our study. To accommodate participants with limited Internet access, we 
developed a pared-down version of the CTD (the “CTD Lite”) that staff complete with 
participants over the phone. As of this writing, we have collected a total of 625 CTDs, which 
have been completed by 92% (n = 134) of participants enrolled in the full-participation arm 
of the study (n = 146). Although participants in the full-participation arm of the study are 
required to complete a CTD every time they screen for studies, continued enrollment in 
Phase I studies is not a requirement of our study.
The structure of the CTD data allows us to compute various metrics that help us understand 
patterns of participation for healthy volunteers. Because participants list the clinic name for 
each clinical trial, we can use these data to calculate distances between clinics and from their 
home address each time participants screen for studies. This allows us to systematically 
track geographical patterns of participation for healthy volunteers in our study to provide a 
clearer picture of the ways in which travel may inform these behaviors. Similarly, although 
compliance with washout periods represents a concern for those who conduct clinical 
studies with healthy volunteers, little is known about the degree to which this behavior 
exists. Dates of participation in studies allow us to compute estimated compliance with the 
Edelblute and Fisher Page 5













wash-out period for participants in our study. Over time, CTD data will allow us to assess 
trends in participation among healthy volunteers in our study and the ways in which their 
experiences in studies inform their future behaviors.
Ethical Considerations
Our study was reviewed and approved by the Biomedical Institutional Review Board (IRB) 
at the University of North Carolina at Chapel Hill. The identities of the participants in our 
study are confidential. Although we enrolled healthy volunteers while they were 
participating in a clinical trial, we do not share with the Phase I clinics any information 
about who enrolled in our study or the information they provide in interviews or CTDs. In 
addition, we hold confidential any information about participants’ dual enrollment in clinical 
trials or their failure to observe washout periods between studies. This level of 
confidentiality is important for participants to trust us with information about their trial 
participation. Because Phase I studies provide intensive monitoring of healthy volunteers’ 
health and wellness, we do not believe that preserving participants’ confidentiality 
endangers them.
Results
To illustrate the capabilities of our tool for reporting Phase I participation, we provide 
examples of the kinds of data that can be collected with the CTD system. Using a case study 
approach, we focus on CTD data over a 6-month period for three participants who were 
enrolled in the same cohort of our study in 2013. We selected these participants because 
they had a higher than average rate of screening for new clinical trials in a 6-month period 
and can illustrate more Phase I activity in a short span of time. Pseudonyms are used to 
protect the confidentiality of our participants, and we label the clinics they visited using the 
letters A to H instead of their proper names. When enrolled in our study, all three were 
participating in a drug interaction study at a clinic in the Midwest noted as “Baseline” at 
Clinic A in Figure 2. This study lasted 10 days and nights and paid US$2,500. As is typical 
of Phase I trials, this study had a washout period of 30 days during which time participants 
were prohibited from enrolling in new clinical studies. The trajectories of each of these three 
participants after departing from this shared study provide a glimpse into how healthy 
volunteers participate serially in clinical trials.
Participant 1
“Steve” is a single White male is his late 40s who estimated that he had participated in 70 
clinical trials since he started participating in studies in the early 1990s. He has traveled 
extensively to participate in Phase I trials in the United States and even participated in one 
overseas. During his baseline interview, he also revealed that he had moved to a new area in 
the Midwest primarily because he liked a particular Phase I clinic there and thought the 
location would be convenient to other clinics in nearby states. Although he works as a 
handyman on occasion, income from Phase I studies represents his primary source of 
income.
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In the first 6 months of his participation in our study, Steve completed seven CTDs for new 
studies, providing information on where he screened, for what types of Phase I trials, the 
outcome of his screening visits, and whether he participated in those studies for which he 
qualified (Figure 2). These CTDs reveal his movements through the Midwest in pursuit of 
clinical trials as well as offer insights into his decision-making process.
Thirteen days after finishing his baseline study (noted as “Study 1” in Figure 2), Steve 
screened for a study at a Clinic B located 425 miles from Clinic A. This Phase I study 
involved an investigational drug for tuberculosis (Study 2). It paid US$5,900 and required 
22 overnight stays over a period of 30 days. Steve qualified for this study and proceeded to 
the clinic to check in on the scheduled start date. At check-in, however, he was informed 
that he was an alternate, and he was dismissed from the study the following day after the 
required number of participants was dosed with the study drug. Six days later, Steve 
screened at the same clinic for Study 3, a Phase I trial of a drug for fungal infections. This 
study paid almost US$9,000 but was much longer than the other, spanning 109 days with 31 
overnight stays. After screening for the study, Steve wrote in his CTD,
It's a lot longer and drawn out than I'd prefer, with 3 outpatient visits over 3 months 
after checkout. But since I didn't get used for the $5,900 [study] I checked into a 
week ago, I need to grab this one. All my other options are too small.
Steve qualified for this study and checked in to the clinic to participate. He was again 
discharged from the study the day after check-in, this time because his labs were out of 
range and the clinic opted to use an alternate instead.
The next day, Steve traveled 150 miles to Clinic C to screen for the Hepatitis C Phase I trial, 
a 21-day study involving 9 overnight stays and paying US$2,600. Steve qualified for this 
study, but he noted in his CTD that he might be an alternate, so 2 days before it was to 
begin, he screened for a different study 375 miles away at Clinic D. Study 5—a different 
fungal infection study—paid US$1,200 and was relatively short, lasting only 12 days with 3 
overnight stays. Steve also qualified for this study and explained in his CTD, “This is my 
back-up plan in case I'm an alternate and not used at the [Clinic C] trial that I'm scheduled to 
check in to 2 days earlier.” Returning to Clinic C for Study 4, Steve checked in, and he was 
again an alternate and was discharged from the study. Clinic C offered Steve a study spot in 
a later cohort of the same study scheduled to begin 10 days later. In the meantime, Steve 
returned to Clinic D for Study 5, but he was again an alternate and was discharged from the 
study. He indicated in his CTD that he was “frustrated, upset, stressed, and disappointed” 
with the outcome.
Returning to Clinic C for the second Hepatitis C study, Steve checked in and completed 
Study 6, a 14-day study with 6 overnight stays and a washout period of 45 days. He received 
US$1,800 in compensation. Twelve days after that study ended, Steve traveled 100 miles to 
screen for Study 7 at Clinic E. He was told that his electrocardiogram (ECG) was out of 
range and did not qualify. Returning to the same clinic 5 days later, he screened for Study 8. 
He qualified for and participated in that 40-day acne study with 6 overnight stays and was 
paid US$2,075. In the final part of his CTD, he reflected, “It was a very short study with 3 
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different 2-night stays. Not my preferred type. But if I still can't find longer, higher paying 
studies, I may have to do one like this again.”
Over this 6-month window and including the baseline study, Steve screened for eight new 
Phase I trials, but participated in only three of those studies. Although he qualified for four 
additional studies, he was an alternate without the clinic needing him on three, and he failed 
to pass all the laboratory tests at check-in for the fourth. He earned more than US$6,000 by 
participating in clinical studies and traveled more than 1,400 miles to screen for studies. He 
used specific strategies, such as qualifying for more than one study at a time and traveling 
within a wide swath of the Midwest, to maximize his chances of participating in studies and 
earning the compensation that comes with participation. For the most part, his screening 
behavior was not in compliance with the specified 30- or 45-day washout periods for studies 
because he sought new studies at a different clinic shortly after completing participation in 
each study.
Participant 2
“Michael” is a single Black male in his late 30s who had participated in 22 studies when he 
enrolled in our study. Michael enrolled in his first Phase I trial in 2008 and, like Steve, 
currently participates in studies full-time. Michael sees himself as an entrepreneur, and he 
uses his income from clinical trials not only to pay his household expenses but also to buy 
and renovate houses as investment properties.
In the first 6 months in our study, Michael completed CTDs for six new Phase I studies. He 
was enrolled in the same drug interaction study as Steve at Clinic A, which was located 350 
miles from his home address. During that study, he was already lining up new screening 
visits by calling other clinics and making plans to carpool to those appointments with a few 
other participants in the study. Five days after completing Study 1, Michael traveled 200 
miles to screen for a cardiovascular disease (CVD) study at Clinic F (Study 2). He did not 
qualify for this study because his blood pressure was too high, and ECG results were out of 
range for the inclusion criteria of the study. In his CTD, Michael reflected on his test results, 
“I hadn't gotten a lot of sleep the night before, and I know one of the things that can affect 
your blood pressure is not getting enough rest. I know I'm healthy.” His next screening visit 
was 13 days later at Clinic E, a clinic 425 miles from Clinic F. Study 3 involved an 
investigational drug for chronic pain, lasted 38 days and nights, and paid US$9,350. Michael 
qualified for this study, but the clinic had more qualified healthy volunteers than it needed 
and he was not selected to participate. Having already lined up for another screening visit, 
Michael screened for his next study 1 week after his prior screening (and 1 day after Study 3 
would have begun). For this study, he traveled 100 miles to Clinic C for a 15-day HIV study 
with 9 overnight stays and paying US$2,450. He qualified for this study and participated.
Two days after Study 4 ended, he returned to Clinic E for Study 5 because the clinic had 
invited him to participate in a new cohort of the chronic pain drug study. He had to re-
screen, but he qualified for and participated in it. When asked in his CTD for this study 
whether he would participate in an identical study in the future, he indicated that he was 
unsure and offered the following observations:
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There were quite a few AE's (Adverse Events) in this particular study depending on 
if you got the drug or not that I witness[ed]. I personally myself don't think I got the 
drug [and got the placebo instead,] but just seeing some of the people going 
through it, their reaction and how our meals were I'm not sure if I would or not 
[participate in an identical study].
Two days after Study 5 ended, Michael screened and qualified for a 17-day rheumatoid 
arthritis study that paid US$3,650 at Clinic C where his washout period from Study 4 was 
now over. He checked in to participate for this study, but he was not selected to dose and 
was discharged on the third day when the clinic knew they would not need him. About not 
being selected, Michael wrote in his CTD,
Study was full, I was told all my labs and everything was fine just wasn't enough 
room in study . . . I would of [sic] liked to attend the study especially when you fill 
[sic] like you know the staff and they know you as a good participant. But 
sometimes this happens with [a] study and [it's] just the business we deal with.
Two weeks later, Michael returned once again to Clinic E and screened for Study 7. By this 
point, his washout period for Study 5 had expired by 2 days, so he was eligible to participate 
in a new study there. He qualified and participated in this 11-day study for an erectile 
dysfunction drug that paid US$2,550.
Over 6 months and including the baseline study, Michael screened for seven studies, out of 
which he qualified for six, participated in four, and earned almost US$17,000. To screen for 
and participate in these clinical trials, Michael rotated between four clinics and traveled at 
least 1,100 miles. By using this strategy, he was able to avoid complying with the required 
washout period between studies during this 6-month time frame.
Participant 3
When “Renee” enrolled in our study, she had participated in nine studies in 2 years. Renee is 
a divorced biracial female in her late 30s who is the primary caretaker for her two children. 
To participate in the drug interaction study at Clinic A, she had traveled 500 miles from 
home. During her baseline interview, she revealed that she had recently quit her full-time 
job to participate in Phase I clinical trials. She also expressed some reticence about enrolling 
in studies with longer term confinement periods because she worries about being away from 
home for too long. At the same time, however, she has traveled extensively throughout the 
East Coast and Midwest to screen for studies.
Renee completed five CTDs for clinical trials for which she screened during the first 6 
months of her involvement in our study. Six days after Study 1 ended, she screened for a 
female sexual dysfunction study at Clinic G located 525 miles from Clinic A and 300 miles 
from her home (Study 2). This 6-day study paid US$1,920 and required five overnight stays. 
She qualified for this study, and 5 days after screening, she checked into the clinic and 
participated in the study. Twenty-three days after Study 2 ended, Renee screened for Study 3 
at Clinic H located approximately 70 miles from her home. This 24-day study with a 16-
night consecutive stay focused on chronic obstructive pulmonary disease (COPD) and paid 
US$3,450. After qualifying, Renee participated in this study and noted in her CTD that she 
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experienced side effects that included “elevated heart rate, night sweats, muscle twitching in 
legs, pins and needle pricks, and increased blood pressure.” She rated the severity of side 
effects as “severe,” or a 3 on a 4-point scale (i.e., mild, moderate, severe, or extreme) and 
used the comment box below the question to write, “Extremely unusual for me. I never had 
symptoms like this with any other study I've done.” As a result of these side effects, she 
noted that she considered dropping out of the study, but she continued to participate because 
the onset of these symptoms was close to the end of the study, and the clinic staff assured 
her she was not in danger. In a final comment box at the end of the CTD, she wrote, “I will 
be much more cautious about any studies I decide to participate in.”
In spite of her negative experience in Study 3, Renee returned to Clinic G 11 days later and 
screened for Study 4, a 16-day psoriasis study. She did not qualify for this study because the 
study sponsor wanted her to provide “ultra-sound proof of a tubal ligation.” Although she 
had undergone a tubal ligation a few years prior, the sponsor would not accept her medical 
records and requested that she undergo an ultrasound at her own expense. When she opted 
not to do this, she was disqualified from the study. Thirty-four days after screening for Study 
4, Renee again returned to Clinic G to screen for a Hepatitis C study that paid US$2,470 and 
required six overnight stays over a 30-day period. She qualified for this study that was 
scheduled to begin 3 weeks after her screening visit. Before Study 5 began, however, Renee 
screened for Study 6 at Clinic F located 725 miles from Clinic G. Study 6 was for diabetes 
renal failure and paid more than US$5,000 and required 20 overnight stays over a 42-day 
period. After qualifying for Study 6, she decided to participate in this study instead of Study 
5 because the study dates overlapped, and Study 6 paid better. She reported that her chosen 
study was relatively easy and one that she would participate in again as she experienced no 
problems or side effects. She further commented in her CTD that this clinic was the best 
facility she had ever been to as a healthy volunteer.
Including her baseline study at enrollment in our study, Renee screened for six clinical trials, 
qualified for five, and participated in four during her initial 6 months of participation in our 
study. She earned approximately US$13,000 by participating in clinical studies and traveled 
at least 1,950 miles to screen for studies during that period. Based on her CTDs, Renee did 
not observe the washout period between Study 1 and 2, but she completed washout periods
—whether intended or not—between the other studies during the remaining time in the 6-
month period reported here.
Discussion
The three cases we present here illustrate how a CTD—the tool we created as part of the 
HealthyVOICES Project—can generate a multidimensional representation of healthy 
volunteer participation in Phase I clinical trials. As these cases demonstrate, participation in 
clinical trials is a way of life for these healthy volunteers and can require extensive travel 
and coordination, but the compensation can make this lifestyle possible. Although the data 
we present provide a 6-month window into the participation of a small subset of healthy 
volunteers in our study, they convey how patterns of behavior can emerge in a relatively 
brief period of time.
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An important finding illustrated by these three cases is the extent to which healthy 
volunteers ignore washout periods between studies. All three participants screened for new 
studies at different clinics less than 2 weeks after finishing Study 1. Indeed, this was fairly 
typical for them throughout the 6-month time period reported here. Completing participation 
in a study at one clinic was often followed by screening for a new study at a separate clinic, 
demonstrating the degree to which participants intended to disregard the required 30- or 45-
day washout periods for studies. Indeed, we found that sometimes washout periods were 
observed simply because participants were prevented from enrolling in a new study as 
quickly as they would have liked. Steve adhered to the washout period for the baseline 
clinical trial only because he was not selected to participate in the four studies for which he 
screened immediately following that study. Renee and Michael also ended up observing 
washout periods for previous studies because they failed to qualify for new studies. In this 
way, observing the washout period is merely an artifact of not successfully gaining quick 
access to a new study, rather than a conscious adherence to the requirements of a prior 
study.
Our findings also indicate that healthy volunteers use the strategy of rotating between select 
clinics. Qualifying for a study at one clinic would provoke another screening at a different 
clinic in Steve's case. For Michael, five of the six studies he screened for were at two clinics 
that were located approximately 100 miles from one another. His washout periods between 
studies at these two clinics structured his screening behaviors. Specifically, participating in a 
study at Clinic C during the washout period for a study at Clinic E provided an opportunity 
to earn income while being temporarily barred from screening at Clinic E. When the 
washout period for Clinic E expired, Michael returned to that clinic to screen for a study. 
Rotating between just these two clinics helped Michael maximize his participation in new 
Phase I trials.
Our data suggest that healthy volunteers create their own system of clinical trial “alternates” 
or backups to maximize their successful enrollment in Phase I studies. Just like Phase I 
clinics engage in various practices such as qualifying more participants than needed to meet 
their study goals, healthy volunteers use specific strategies to meet their primary goal of 
maximizing their earning potential through participation in Phase I studies. Our results show 
that healthy volunteers screen for multiple studies at a time to increase their chances of 
participation, knowing that they might not qualify for one or that they are only an alternate 
and not guaranteed participation in another. On one hand, Steve's history of being an 
alternate in studies for which he qualified catalyzed him to create his own system of clinical 
trial alternates. The time between finding out about qualifying for a study and the study start 
date served as an opportunity to develop a “back-up plan” aimed at improving his odds of 
participation in any study. Renee, on the other hand, qualified for a study scheduled to start 
3 weeks later, but decided to screen in the interim for another study that paid better and—
because the study dates overlapped—chose to participate in the higher paying one.
Another important finding from these three cases is that experiences in past studies can 
influence how healthy volunteers perceive the risks of studies and shape future decisions 
regarding participation in Phase I trials. Renee experienced severe side effects that included 
night sweats, muscle twitching, and the sensation of pins and needles or paresthesia in a 
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COPD study. She considered dropping out of that study due to the severity of these side 
effects and noted that she would be more careful when making decisions about future 
studies. Michael had a similar experience while participating in a chronic pain study. His 
observation of other participants experiencing adverse effects led him to believe that he was 
dosed with the placebo instead of the study drug and made him question whether he would 
participate in a similar study in the future. Further data, collected over the course of the 
HealthyVOICES Project, will be able to document whether and how these concerns affect 
their decisions about future study participation.
The 6-month participation trajectories of all three healthy volunteers demonstrate active 
patterns of screening for clinical trials at Phase I clinics. However, the amount of effort it 
took to enroll successfully in studies and earn compensation varied across our participants. 
After his baseline study, Steve qualified for four studies before finally participating in one; 
indeed, he participated in only two of the seven studies for which he screened. He traveled at 
least 1,200 miles before finally being enrolled in a second study, demonstrating the amount 
of effort the pursuit of studies can take. Steve noted that the study he finally participated in 
was not his preferred type given its short duration and relatively low pay, but felt like he had 
no other options. He earned about US$6,000 from his study participation during this 6-
month period. Michael, by contrast, earned almost US$17,000 for participating in four 
studies and mostly traveled between two clinics located just 100 miles apart. The longer 
confinement study for the chronic pain drug paid more than US$9,000 and comprised the 
majority of the income he earned during this time. Renee earned approximately US$13,000 
during this time period, but traveled at least 2,500 miles in her pursuit of studies during this 
time. The lengths to which healthy volunteers go to participate in Phase I trials varied as did 
the rewards for these efforts.
The case studies represent in-depth examinations of individual patterns of behavior over a 6-
month period for three healthy volunteers who were enrolled in the same cohort of our 
study. The three volunteers we selected had extensive experience in clinical studies and had 
been participating in studies for a number of years when they enrolled in our study. Their 
experiences provide a snapshot of possible participation trajectories, but are not meant to be 
generalizable given the case study approach. Instead, by selecting participants who 
frequently screen for and participate in studies, we aimed to demonstrate the value of the 
CTD as a tool that can uncover healthy volunteers’ patterns of participation in Phase I 
clinical trials. Future analyses of the CTD data can examine not only how individuals’ 
behaviors might change over time but also how subgroups of participants in our study differ 
based on their socio-demographic characteristics or their level of clinical trial experience.
Research Agenda
The preliminary findings from these case studies of serial participants in clinical studies 
suggest that the financial incentives associated with Phase I participation outweigh healthy 
volunteers’ adherence to restrictions designed to protect their health. What repeated failure 
to observe wash-out periods could mean for the well-being of healthy volunteers over time 
is an open question. This highlights the need for further research on the long-term health 
consequences of serial participation in clinical trials. A study like ours can provide data on 
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what clinical trials healthy volunteers screen for and enroll in, but as a social science project, 
we are not monitoring the health outcomes of our participants. A comparative study of 
healthy volunteers and non-trial participants as “matched controls,” for example, would 
generate important information about the long-term effects of repeated exposure to 
investigational drugs. This type of research would also provide critical information to 
healthy volunteers about the longer term risks of Phase I serial participation.
In addition, repeated failure to observe washout periods has implications for the integrity of 
clinical trial data and represents a concern for the pharmaceutical companies sponsoring 
these studies. Some clinics have begun using proprietary participant tracking tools, such as 
Verified Clinical Trials and clinicalRSVP, to prevent participants from simultaneously 
enrolling in multiple studies or being noncompliant with washout periods. These databases 
can provide useful information for research clinics to prevent such occurrences. However, 
these systems have not been widely adopted, so participating clinics only know about 
healthy volunteers’ participation in studies at the clinics that have subscribed to each system. 
In our ongoing study, we are finding that healthy volunteers are aware of which clinics use 
these systems and factor that information into their participation strategies. Future research, 
more broadly, should examine the ways in which clinic characteristics and industry changes 
structure participation for healthy volunteers over time and how to best ensure the validity of 
clinical trial data.
Educational Implications
Currently, medical researchers and IRBs are trained to evaluate clinical trials as discrete 
protocols that present specific risks and benefits to research participants. A study like ours 
suggests that Phase I healthy volunteers create unique challenges for human subject 
protections because of their serial participation. By acknowledging the broader risks 
generated by healthy volunteers’ screening and enrollment behaviors, researchers and IRBs 
should reimagine how risk information is provided to healthy volunteers. Rather than simply 
stating inclusion criteria that would exclude participants who have recently completed a 
Phase I trial, there is a need for greater attention to educating participants to the risks of 
serial participation. Specifically, providing more detailed information about the potential 
health consequences of ignoring washout periods or other restrictions on their study 
participation could encourage healthy volunteers to exercise greater caution and provide 
more honest information during the screening process.
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Design of clinical trial diary (CTD) system.
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Clinical trial participation trajectories.
Note. CVD = cardiovascular disease; COPD = chronic obstructive pulmonary disease.
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Table 1





    18-21 6 3.3
    22-29 34 18.9
    30-39 58 32.2
    40-49 56 31.1
    50-54 16 8.9
    55+ 10 5.6
Race/ethnicity
    Non-Hispanic White 57 31.7
    Black 73 40.5
    Hispanic 36 20.0
    Other
a 14 7.8
Foreign born 35 19.4
Clinical trial experience
    1 study 38 21.1
    2-4 studies 50 27.7
    5-10 studies 46 25.6
    11-200 studies 46 25.6
a
Other includes non-Hispanic respondents who are American Indian (n = 2), Asian (n = 6), native Hawaiian or other Pacific Islander (n = 1), or 
more one race (n = 6).
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